STOCK TITAN

Oncolytics Biotech Inc. - $ONCY STOCK NEWS

Welcome to our dedicated page for Oncolytics Biotech news (Ticker: $ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.

Oncolytics Biotech Inc. (symbol: ONCY) is a pioneering biotechnology company dedicated to the development of oncolytic viruses as innovative cancer therapeutics. Their flagship product, pelareorep, is a unique immunotherapeutic agent designed to harness the power of the human reovirus to enhance the body's immune response against cancer. Pelareorep has shown promising potential in making tumors more responsive to a variety of oncology treatments by promoting an inflamed tumor phenotype.

The company's robust clinical development pipeline includes multiple human trials targeting some of the most prevalent cancers, such as breast, gastrointestinal, and pancreatic cancers. Notably, Oncolytics is conducting a Phase III trial for head and neck cancers and has several ongoing trials in advanced stages, including the GOBLET study, which explores the efficacy of pelareorep in combination with different chemotherapy regimens.

In breast cancer, Oncolytics is advancing towards registration-enabling studies for HR+/HER2- metastatic breast cancer, supported by compelling data from the BRACELET-1 and IND-213 randomized studies. The company is also making significant strides in pancreatic cancer research, recently receiving a US$5 million grant from the Pancreatic Cancer Action Network (PanCAN) for a new Phase 1/2 cohort in the GOBLET study, assessing pelareorep in combination with modified FOLFIRINOX and atezolizumab (Tecentriq®).

Financially, Oncolytics is well-positioned with a strong balance sheet and ongoing support from strategic partnerships and grants. The company’s collaborations with leading research institutions and oncology networks enhance its clinical programs and accelerate the development of pelareorep as a versatile cancer therapy. Oncolytics continues to innovate and push the boundaries of cancer treatment, aiming to bring new hope to patients worldwide.

Rhea-AI Summary

Oncolytics Biotech presented two abstracts at the 2024 ASCO Annual Meeting that highlight the potential of pelareorep in treating metastatic pancreatic ductal adenocarcinoma (PDAC) and its immunotherapeutic mechanism of action.

The first abstract discusses a new cohort in the GOBLET study, which will test pelareorep combined with mFOLFIRINOX, with and without atezolizumab. This cohort is funded by a $5 million grant, expecting enrollment to start this quarter.

The second abstract highlights pelareorep's ability to induce tumor-infiltrating lymphocytes (TILs) expansion, correlating with improved tumor response across multiple cancers, providing further support for its use as a backbone immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
none
-
Rhea-AI Summary

On May 16, 2024, Oncolytics Biotech announced the voting results from its Annual General Meeting held on May 15, 2024. Representing 41.34% of outstanding shares, shareholders elected eight directors with the following votes: Patricia Andrews (84.78%), Deborah M. Brown (74.81%), Matthew C. Coffey (70.97%), Angela Holtham (77.53%), James T. Parsons (74.81%), Wayne Pisano (72.88%), Jonathan Rigby (76.81%), and Bernd R. Seizinger (81.49%).

Additionally, shareholders approved the number of directors at eight and reappointed the auditors for the coming year. For more details, refer to the management information circular at SEDAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
none
-
Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY) announced a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR) to include pelareorep in a planned pancreatic cancer trial. The trial will use a combination therapy of checkpoint inhibition and chemotherapy, and aims to accelerate the development timeline while reducing costs. The adaptive Phase 2/3 design will assess multiple investigational therapies for metastatic pancreatic cancer, providing a potential registration pathway. Updated data from the GOBLET study showed a 62% objective response rate with pelareorep, nearly triple the historical control trials. This strategic collaboration is expected to advance the development of pelareorep to address urgent patient needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
Rhea-AI Summary

Oncolytics Biotech® reported first-quarter 2024 financial results and operational highlights including advancing pelareorep to registration-enabling studies, obtaining FDA Type C meeting for HR+/HER2- metastatic breast cancer, and anticipated milestones like overall survival data in H2 2024. The company has a cash position of $29.6 million providing runway into 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
-
Rhea-AI Summary

Oncolytics Biotech Inc. has received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRINOX and an anti-PD-L1 inhibitor in pancreatic cancer. The company will start enrollment in a new GOBLET study cohort, supported by a $5M grant from PanCAN, with the first patient expected to be enrolled in Q2 2024. The study aims to enhance pelareorep's potential in addressing pancreatic cancer and expand its role in providing benefits to patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
Rhea-AI Summary

Oncolytics Biotech® Inc. (NASDAQ: ONCY) will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference. Dr. Matt Coffey, the CEO, will be speaking at the event taking place on May 14-15, 2024, in New York. The company will also hold one-on-one investor meetings and provide a live webcast of the presentation on its website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
Rhea-AI Summary

Oncolytics Biotech® announced a conference call and webcast to discuss corporate updates and financial results for the first quarter of 2024. The event will take place on May 9, 2024, at 4:30 p.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
conferences earnings
-
Rhea-AI Summary
Oncolytics Biotech® Inc. announces the acceptance of two abstracts at the 2024 American Society of Clinical Oncology Annual Meeting. The abstracts focus on pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma and blood TIL expansion in patients with pancreatic, breast, and colon cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences
-
Rhea-AI Summary
Oncolytics Biotech Inc. announces a Type C meeting request with the FDA for a registration-enabling trial in HR+/HER2- metastatic breast cancer. Positive results from the BRACELET-1 trial and upcoming overall survival data in H2 2024 indicate a transformative year ahead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
Rhea-AI Summary
Oncolytics Biotech® Inc. President and CEO, Dr. Matt Coffey, will join the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 15, 2024. The company will also hold virtual investor meetings at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences

FAQ

What is Oncolytics Biotech Inc. known for?

Oncolytics Biotech Inc. is known for developing pelareorep, an innovative oncolytic virus used as a potential cancer therapeutic to enhance the immune system's response to tumors.

What cancers is Oncolytics currently targeting?

Oncolytics is targeting a variety of cancers including breast, gastrointestinal, pancreatic, and head and neck cancers through its clinical trials and research programs.

What is pelareorep?

Pelareorep is Oncolytics Biotech’s proprietary formulation of the human reovirus, designed to stimulate immune responses and make tumors more susceptible to a range of oncology treatments.

What are the recent achievements of Oncolytics Biotech?

Recent achievements include advancing to Phase III trials in head and neck cancers, receiving a US$5 million grant for pancreatic cancer research, and positive Phase 2 data in metastatic breast cancer.

How is Oncolytics Biotech funded?

Oncolytics Biotech is funded through a mix of strategic partnerships, grants, and a robust cash position to support its clinical development programs and operations.

What is the GOBLET study?

The GOBLET study is a Phase 1/2 clinical trial exploring the efficacy of pelareorep in combination with chemotherapy and checkpoint inhibitors in gastrointestinal cancers, particularly pancreatic cancer.

What are the potential benefits of pelareorep?

Pelareorep has demonstrated potential benefits such as enhancing the immune system's ability to fight cancer, increasing tumor susceptibility to treatments, and promoting an inflamed tumor phenotype.

What is the focus of Oncolytics' current clinical trials?

Oncolytics' clinical trials focus on leveraging pelareorep in combination with various chemotherapy regimens and immunotherapies to treat multiple cancer types effectively.

What partnerships does Oncolytics Biotech have?

Oncolytics partners with leading research institutions, oncology networks, and pharmaceutical companies to accelerate the development and commercialization of its therapies.

Where can I find more information about Oncolytics Biotech?

More information about Oncolytics Biotech can be found on their official website at www.oncolyticsbiotech.com or through their social media channels on LinkedIn and X (formerly Twitter).

Oncolytics Biotech Inc.

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

76.93M
66.96M
6.16%
6.88%
1.23%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Calgary